English court resumes Amgen cholesterol patent suit
23-10-2020
Kilpatrick Townsend hires litigation team from DLA Piper
19-10-2020
Casimiro PT / Shutterstock.com
Regeneron Pharmaceuticals is facing claims that its “antibody cocktail”, which was administered to President Donald Trump to treat his COVID-19 symptoms, was developed with the unauthorised use of a fluorescent protein.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Regeneron, Pfizer, COVID-19, protein, mNeonGreenprotein, Allele, biotechnology, royalties, mNeonGreen
